Physician profile
Angel E Tafur
NPI 1801892401
$1,626.20
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $153 · 2021: $356 · 2022: $359 · 2023: $186 · 2024: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.59 | 2020-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $257.57 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.92 | 2022 | |
| Exact Sciences Corporation | $123.30 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.20 | 2019 | |
| Glaxosmithkline, LLC. | $100.87 | 2023 | |
| Sunovion Pharmaceuticals INC. | $85.69 | 2019-2020 | |
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Pfizer INC. | $82.31 | 2022-2024 | |
| Abbvie INC. | $33.13 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $28.04 | 2019-2020 | |
| Lundbeck LLC | $17.48 | 2023 | Rexulti |
| Amgen INC. | $17.34 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $15.60 | 2020 | |
| Novo Nordisk INC | $14.04 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.76 | 2020 | |
| Abbott Laboratories | $13.32 | 2022 | |
| Biogen, INC. | $11.70 | 2021 | |
| Amarin Pharma, INC. | $11.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Tafur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.